Expertise

Targeted Nuclear Medicine

Radiopharmaceuticals

ABX-CRO has more than 30 years of unique experience developing diagnostic and therapeutic radiopharmaceuticals from bench to bedside. Our experience from more than 70 radiopharmaceutical trials phase 0–III includes alpha, beta, Auger, PET and SPECT radionuclides, labelled to pharmacophores ranging from small molecules, peptides, and antibodies to medical devices.

Strategic Consultancy

Project Design & Strategy Consultancy

• Strategy (indication, medical environment, IP supply, regulatory)
• Scientific advice procedures
• Integrated protocol development campaigns with joint Key Opinion Leader panels from target and technical disciplines
• Extensive project de-risking using advanced literature-based sample-size estimations and risk-factor simulations
• In-depth medical and technical feasibility with global coverage

Clinical Execution

Clinical Operations

• Project Management by academically trained PMs experienced in complex multinational programmes phase I–III
• Monitors/CRAs with advanced educational backgrounds, specialised in oncology and imaging
• Clinical Trial Administration run by experienced medical documentalists
• Integrated support: Regulatory, Data Management, IP logistics

Imaging & Dose Intelligence

Molecular Imaging
& Dosimetry

• Turnkey PET, SPECT, whole-body planar, CT and MRI imaging
• Site setup, training, phantom measurements, calibration and radionuclide logistics
• Image data management and quantitative analysis, including RECIST, PERCIST and advanced endpoints
• Preclinical dosimetry, human dose estimation and nuclide exchange calculations
• Safety and efficacy dosimetry with voxel-level mapping (OLINDA/EXM, IDAC-Dose 2.1), plus multi alpha-decay dosimetry for Ac-225, Ra-223 and Th-227 (IDAC-alpha)

Explore our Imaging & Dosimetry Solutions